Published on 15 Feb 2024 on GuruFocus.com via Yahoo Finance
Strengths: Pioneering RNAi therapeutics with a robust product portfolio and strategic collaborations.Weaknesses: High operational costs and reliance on successful product commercialization.Opportunities: Expansion into prevalent disease markets and ongoing clinical trials.Threats: Intense competition and regulatory challenges impacting product approvals.
Warning! GuruFocus has detected 2 Warning Sign with ALNY.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, filed its 10-K on February 15, 2024, revealing a year of strategic advancements and financial growth. With a market capitalization of approximately $23.65 billion as of June 30, 2023, and a workforce of about 2,100 employees, ALNY has established itself as a formidable player in the biopharmaceutical industry. The company reported net product revenues of $1.24 billion for the fiscal year ended December 31, 2023, indicating a strong commercial presence. Despite a history of losses, with an accumulated deficit of $7.01 billion, ALNY's strategic initiatives and product launches suggest a trajectory towards achieving a self-sustainable financial profile. This SWOT analysis delves into the strengths, weaknesses, opportunities, and threats as disclosed in the latest SEC filing, providing investors with a comprehensive understanding of ALNY's current position and future outlook.